{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:59:04Z","timestamp":1790773144130,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016018","name":"Universidad El Bosque","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.autrev.2023.103393","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T19:28:07Z","timestamp":1690054087000},"page":"103393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Posttranslational modifications in psoriatic arthritis: A systematic literature review"],"prefix":"10.1016","volume":"22","author":[{"given":"Omar-Javier","family":"Calixto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Alejandra","family":"Meneses-Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward-Camilo","family":"Vera-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Manuel","family":"Bello-Gualtero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Romero-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103393_bb0005","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/art.24608","article-title":"The prevalence of psoriatic arthritis in people with psoriasis","volume":"61","author":"Ibrahim","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103393_bb0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7453\/gahmj.2012.1.4.009","article-title":"Psoriatic arthritis","volume":"1","author":"Fitzgerald","year":"2012","journal-title":"Glob Adv Health Med"},{"key":"10.1016\/j.autrev.2023.103393_bb0015","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2023.103393_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baab012","article-title":"Posttranslational modifications in proteins: resources, tools and prediction methods","volume":"2021","author":"Ramazi","year":"2021","journal-title":"Database"},{"key":"10.1016\/j.autrev.2023.103393_bb0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2023.103393_bb0030","series-title":"Study quality assessment tools","author":"National Institute of Health","year":"2014"},{"key":"10.1016\/j.autrev.2023.103393_bb0035","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)","author":"Higgins","year":"2021"},{"key":"10.1016\/j.autrev.2023.103393_bb0040","series-title":"The National Institutes of Health (NIH) quality assessment tool for observational cohort and cross-sectional studies","first-page":"1","author":"National Heart Lung and Blood Institute","year":"2021"},{"key":"10.1016\/j.autrev.2023.103393_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14397595.2019.1586085","article-title":"Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis","volume":"30","author":"Hagiwara","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0050","first-page":"1008","article-title":"Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody","volume":"51","author":"Dai","year":"2019","journal-title":"Beijing Da Xue Xue Bao"},{"key":"10.1016\/j.autrev.2023.103393_bb0055","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00296-014-2956-8","article-title":"Are anti-CCP antibodies in psoriatic arthritis patients a biomarker of erosive disease?","volume":"34","author":"Perez-Alamino","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103393_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320986722","volume":"12","author":"Rotondo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0065","first-page":"376","article-title":"Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--Cross-sectional study and literature review","volume":"6","author":"Popescu","year":"2013","journal-title":"J Med Life"},{"key":"10.1016\/j.autrev.2023.103393_bb0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/rhu.0000242779.73390.51","article-title":"Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis","volume":"12","author":"Candia","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/ard.2005.040998","article-title":"Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation","volume":"65","author":"Alenius","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3892\/br.2020.1343","article-title":"Assessment of serum levels of anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: a cross-sectional study in a Brazilian cohort","volume":"13","author":"Gruber","year":"2020","journal-title":"Biomed Rep"},{"key":"10.1016\/j.autrev.2023.103393_bb0085","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/keh686","article-title":"The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis","volume":"44","author":"Korendowych","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103393_bb0090","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/14397595.2020.1761070","article-title":"Prevalence of anti-cyclic citrullinated peptide antibodies in patients with spondyloarthritis: a retrospective study","volume":"31","author":"Yamazaki","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdermsci.2008.06.008","article-title":"Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis","volume":"53","author":"Shibata","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2023.103393_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1346-8138.2010.00814.x","article-title":"Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients","volume":"37","author":"Maejima","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10067-006-0214-5","article-title":"Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis","volume":"26","author":"Inanc","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0110","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/rheumatology\/kew229","article-title":"Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis","volume":"55","author":"Behrens","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103393_bb0115","first-page":"511","article-title":"Antibodies to cyclic citrullinated peptides in psoriatic arthritis","volume":"32","author":"Bogliolo","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10067-009-1345-2","article-title":"Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis","volume":"29","author":"Tesija-Kuna","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-0500-2-44","article-title":"Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis","volume":"2","author":"Abdel Fattah","year":"2009","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.autrev.2023.103393_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.21691","article-title":"Synovial fluid levels of anti\u2013cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis","volume":"55","author":"Caspi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103393_bb0135","first-page":"599","article-title":"Anti-cyclic citrullinated peptide antibody determination in synovial fluid of psoriatic arthritis","volume":"25","author":"Spadaro","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0140","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3899\/jrheum.131375","article-title":"Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients","volume":"41","author":"Payet","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/474028","article-title":"Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris","volume":"2013","author":"Dalm\u00e1dy","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2023.103393_bb0150","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/ard.2009.108456","article-title":"Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis","volume":"69","author":"Damjanovska","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0155","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2004.032177","article-title":"Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis","volume":"64","author":"Vander Cruyssen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0160","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1186\/ar2802","article-title":"Diagnostic and prognostic value of antibodies against chimeric fibrin\/filaggrin citrullinated synthetic peptides in rheumatoid arthritis","volume":"11","author":"Sanmart\u00ed","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103393_bb0165","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fimmu.2018.01113","article-title":"Comparison of serological biomarkers in rheumatoid arthritis and their combination to improve diagnostic performance","volume":"9","author":"Martinez-Prat","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103393_bb0170","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3899\/jrheum.170446","article-title":"Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis","volume":"45","author":"Lac","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0175","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1515\/cclm-2014-0683","article-title":"Automated immunoassays for the autoantibodies to carbamylated or citrullinated telopeptides of type I and II collagens","volume":"53","author":"H\u00e4yrynen","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.autrev.2023.103393_bb0180","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/rheumatology\/kem193","article-title":"IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders","volume":"46","author":"Anzilotti","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103393_bb0185","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","article-title":"Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis","volume":"7","author":"Kruithof","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103393_bb0190","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2006.054924","article-title":"Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines","volume":"66","author":"Hueber","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0195","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103393_bb0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejr.2017.08.002","article-title":"Anti-carbamylated protein antibodies in psoriatic arthritis patients: relation to disease activity, severity and ultrasonographic scores","volume":"40","author":"Ibrahim","year":"2018","journal-title":"Egypt Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s42358-019-0096-2","article-title":"Usefullnes of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?","volume":"59","author":"Tecer","year":"2019","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0210","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.autrev.2015.08.003","article-title":"Auto-reactions, autoimmunity and psoriatic arthritis","volume":"14","author":"Chimenti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103393_bb0215","first-page":"1572","article-title":"Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment","volume":"52","author":"Collins","year":"2013","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.autrev.2023.103393_bb0220","first-page":"867","article-title":"Changes of glycosylation of serum proteins in psoriatic arthritis, studied by enzyme-linked lectin assay (ELLA), using concanavalin a","volume":"46","author":"Saso","year":"1998","journal-title":"Biochem Mol Biol Int"},{"key":"10.1016\/j.autrev.2023.103393_bb0225","first-page":"225","article-title":"Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation","volume":"21","author":"Triolo","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0230","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/1529-0131(199908)42:8<1682::AID-ANR17>3.0.CO;2-X","article-title":"Sugar printing rheumatic diseases: a potential method for disease differentiation using immunoglobulin G oligosaccharides","volume":"42","author":"Watson","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103393_bb0235","first-page":"96","article-title":"Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment","volume":"26","author":"Lories","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.758418","article-title":"High dimensional analyses of circulating immune cells in psoriatic arthritis detects elevated phosphorylated STAT3","volume":"12","author":"Macaubas","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103393_bb0245","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2012.06.316","article-title":"IL-22 induced cell proliferation is regulated by PI3K\/Akt\/mTOR signaling cascade","volume":"60","author":"Mitra","year":"2012","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2023.103393_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672461","article-title":"Targeting JAK-STAT signalling alters PsA synovial fibroblast pro-inflammatory and metabolic function","volume":"12","author":"O\u2019Brien","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103393_bb0255","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12967-021-03006-x","article-title":"Identification of proteins associated with development of psoriatic arthritis in peripheral blood mononuclear cells: a quantitative iTRAQ-based proteomics study","volume":"19","author":"Zhu","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.autrev.2023.103393_bb0260","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/exd.13790","article-title":"Histone modifications associated with biological drug response in moderate-to-severe psoriasis","volume":"27","author":"Ovejero-Benito","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0265","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jcla.20243","article-title":"Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients","volume":"22","author":"Firuzi","year":"2008","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.autrev.2023.103393_bb0270","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1211\/jpp.58.7.0010","article-title":"Oxidative stress parameters in different systemic rheumatic diseases","volume":"58","author":"Firuzi","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.autrev.2023.103393_bb0275","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/jb\/mvz096","article-title":"Effect of redox imbalance on protein modifications in lymphocytes of psoriatic patients","volume":"167","author":"W\u00f3jcik","year":"2020","journal-title":"J Biochem"},{"key":"10.1016\/j.autrev.2023.103393_bb0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0285","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.autrev.2016.03.003","article-title":"Autoantibodies in inflammatory arthritis","volume":"15","author":"Conigliaro","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103393_bb0290","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/JIR.S339296","article-title":"Emerging roles of post-translational modifications in skin diseases: current knowledge, challenges and future perspectives","volume":"15","author":"Yang","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.autrev.2023.103393_bb0295","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/rheumatology\/ken077","article-title":"Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides","volume":"47","author":"Tilleman","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103393_bb0300","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103393_bb0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5114\/aoms.2011.22067","article-title":"Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis","volume":"7","author":"Puszczewicz","year":"2011","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.autrev.2023.103393_bb0310","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/ard.2008.105759","article-title":"Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study","volume":"69","author":"Bos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0315","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14737159.2021.1933946","article-title":"Advances in the diagnosis of autoimmune diseases based on citrullinated peptides\/proteins","volume":"21","author":"Alghamdi","year":"2021","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.autrev.2023.103393_bb0320","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40744-022-00427-y","article-title":"The role of shared epitope in rheumatoid arthritis prognosis in relation to anti-citrullinated protein antibody positivity","volume":"9","author":"Zhuo","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2023.103393_bb0325","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/728610","article-title":"The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"2015","author":"Jilani","year":"2015","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103393_bb0330","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.autrev.2009.04.006","article-title":"Anti-citrullinated protein\/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis","volume":"9","author":"Szodoray","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103393_bb0335","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13075-015-0860-6","article-title":"The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis","volume":"17","author":"Shi","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103393_bb0340","first-page":"512","article-title":"Biomarkers in rheumatoid arthritis","volume":"19","author":"Atzeni","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2023.103393_bb0345","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1073\/pnas.87.5.1978","article-title":"Defective cAMP-dependent phosphorylation of intact T lymphocytes in active systemic lupus erythematosus","volume":"87","author":"Hasler","year":"1990","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.autrev.2023.103393_bb0350","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1093\/rheumatology\/keab095","article-title":"Post-translational modifications in T cells in systemic erythematosus lupus","volume":"60","author":"Yang","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103393_bb0355","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.191.4.603","article-title":"The intestinal T cell response to \u03b1-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase","volume":"191","author":"Arentz-Hansen","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2023.103393_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105412","article-title":"Posttranslational modifications as therapeutic targets for intestinal disorders","volume":"165","author":"Choo","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2023.103393_bb0365","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.3748\/wjg.14.5851","article-title":"FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice","volume":"14","author":"Nishimura","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2023.103393_bb0370","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2006.01.020","article-title":"Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus","volume":"370","author":"Khan","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2023.103393_bb0375","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbrc.2007.12.178","article-title":"Involvement of thioredoxin reductase 1 in the regulation of redox balance and viability of rheumatoid synovial cells","volume":"367","author":"Kabuyama","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2023.103393_bb0380","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/10715760701684809","article-title":"Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis","volume":"41","author":"Morgan","year":"2007","journal-title":"Free Radic Res"},{"key":"10.1016\/j.autrev.2023.103393_bb0385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1756-185X.2011.01630.x","article-title":"Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity","volume":"14","author":"Hassan","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103393_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.freeradbiomed.2018.05.086","article-title":"Oxidative stress in autoimmune rheumatic diseases","volume":"125","author":"Smallwood","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.autrev.2023.103393_bb0395","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1039\/C8AN02014K","article-title":"Distribution of abnormal IgG glycosylation patterns from rheumatoid arthritis and osteoarthritis patients by MALDI-TOF-MSn","volume":"144","author":"Sun","year":"2019","journal-title":"Analyst"},{"key":"10.1016\/j.autrev.2023.103393_bb0400","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.3389\/fimmu.2018.03033","article-title":"Differential ACPA binding to nuclear antigens reveals a PAD-independent pathway and a distinct subset of acetylation cross-reactive autoantibodies in rheumatoid arthritis","volume":"9","author":"Lloyd","year":"2018","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:27Z","timestamp":1761600507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1568997223001271"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103393","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posttranslational modifications in psoriatic arthritis: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103393"}}